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hThe success of aggressive pharmacological therapy
in the prevention and treatment of cardiovascular
disease continues to give us renovated energy and
constructive hope. Within the last decade, the
incidence of acute myocardial infarction in the U.S.
population showed a steady decrease. Ten years ago,
in 2002, the annual hospitalization rate was 1,131
See page 169
per 100,000 Medicare beneficiaries. This number
fell to 866 in 2007, a 23% decline (1). Other studies
have confirmed this observation (2), with an im-
pressive 31% reduction in death attributable to
cardiovascular disease from 1998 to 2008 (3). De-
spite these improvements, cardiovascular disease
continues to be the major cause of death in devel-
oped countries, and atherothrombosis is responsible
for the majority of these events.
Atherothrombosis and High-Risk Plaques
Vulnerable plaques are the main cause of thrombo-
sis and are characterized by large atheroma volume,
increased necrotic core, reduced fibrous cap thick-
ness, and inflammation. Establishing which of
these high-risk features will trigger acute coronary
syndromes (ACS) became possible by applying
novel imaging techniques to prospective human
studies. Using computed tomography angiography,
Motoyama et al. (4) identified 2 important features
in the development of ACS: positive remodeling
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ships relevant to the contents of this paper to disclose.large atheroma volume), and low attenuation
laques (increased necrotic core). An impressive
2% event rate was documented for plaques with
oth features. On the optimistic side, the incidence
as only 4.4% of the population studied. Most
mportantly, when treated with statins, these low
ttenuated plaques showed significant reductions in
theroma volume (5). Using a more invasive ap-
roach, the PROSPECT (Providing Regional Obser-
ations to Study Predictors of Events in the Coronary
ree) study (6) identified 3 independent predictors for
uture cardiovascular events in nonobstructive coro-
ary lesions from patients with ACS. These predictors
ncluded thin-cap fibroatheroma, plaque burden
70%, and minimal luminal area 4 mm2. A 17%
vent rate was documented for plaques with all 3
eatures. The incidence was 4.2% of the population
tudied, remarkably similar to the 4.4% previously
dentified in the Motoyama study (4). These crucial
ata of natural history were obtained by a combi-
ation of computed tomography angiography, in-
ravascular ultrasound, and backscattered intravas-
ular ultrasound analysis, also known as virtual
istology. We learned that although infrequent,
dentification of very high-risk plaques is of signif-
cant clinical relevance, but will require simultane-
us, multiple imaging technology (7).
Considering the limitations in imaging resolu-
ion, only a few studies evaluated fibrous cap thick-
ess in vivo (8). However, it is clear that ACS
esults from fibrous plaque digestion and rupture,
ostly by activated macrophages. Also known as
he “Achilles heel” of the plaque, this rim of
ollagen is the last barrier between stability and
hrombosis. Fibrous cap integrity consolidates the
ifference between life and death in patients with
igh-risk atherosclerosis. Nevertheless, studies an-
lyzing fibrous cap response to therapy are lacking.
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179The Present Study
In this issue of iJACC, Hattori et al. (9) contribute
to current knowledge providing evidence of the
effects of statins on the fibrous cap in human
coronary atheroma. Careful structural analysis of
oronary plaques using multimodality imaging tech-
ology before and after 9 months of pitavastatin therapy
as performed. Grayscale and integrated-backscattered
ntravascular ultrasound, and optical coherence to-
ography documented significant reductions in per-
entage of plaque volume index, percentage of lipid
olume index, and a significant increase in fibrous
ap thickness, respectively. Pitavastatin was associ-
ted with a 6% reduction in plaque volume index.
his reduction in atheroma volume is higher than
xpected for a U.S. population using an
torvastatin-like medication with a mean low-
ensity lipoprotein cholesterol plasma level of 89 
23 mg/dl at follow-up. Nevertheless, these results
go along with previously observed reductions in
atheroma volume using the same medication in the
Japanese population (10). The investigators also
documented a 6% reduction in lipid volume with
similar increase in fibrous volume index (9). Of
significant relevance, paired optical coherence to-
mography analysis before and after pitavastatin
documented an increase of 52  32 m in fibrous
cap thickness. These changes in cap thickness
involve a newly synthesized extracellular matrix,
probably mediated by synthesis of reparative type
III collagen (Fig. 1). Increases in cap thickness, in
conjunction with changes in lipid volume constitute
major advances in the field, but should be evaluated
in conjunction with the evidence documented in
previously published studies.
Figure 1. Polarized Microscopy With Picrosirius Red Staining To
and Collagen Composition in Human Aortic Plaques
(A) Thin-cap ﬁbroatheroma mostly composed by structural, type I c
posed by reparative, type III collagen recently synthesized as a hea
Mount Sinai Hospital, 2011; used with permission.Statin Therapy, Atheroma Volume, and
Changes in Plaque Composition
Within the last decade, statins have been shown to
reduce plaque burden in a number of imaging
studies. Corti et al. (11) documented significant
reductions in carotid lesions using magnetic reso-
nance imaging in patients treated with high dose–
simvastatin. The REVERSAL (Reversal of Ath-
erosclerosis with Aggressive Lipid Lowering) study
documented a beneficial effect of high-dose atorv-
astatin showing stabilization of the disease, com-
pared with a statistically significant progression of
atheroma volume ( 2.7%) in the control group
(12). In addition, the ASTEROID (Study to Eval-
uate the Effect of Rosuvastatin on Intravascular
Ultrasound-Derived Coronary Atheroma Burden)
study documented a median 6.8% reduction in
atheroma volume in ACS patients treated with 40
mg of rosuvastatin daily (13). More recently, the
SATURN (Study of Coronary Atheroma by Intra-
vascular Ultrasound: Effect of Rosuvastatin versus
Atorvastatin) study documented 1.22% to 0.99%
reductions in percentage of atheroma volume for
both medications, respectively (14). Plaque regres-
sion was seen in the majority of patients, 68% and
63%, respectively. Despite the small reductions in
percentage of atheroma volume, the changes in
plaque composition may have a much more rele-
vant role clinically. In the SATURN study, the
incidence of death and acute myocardial infarc-
tion was only 1.9% for both medications (14).
The histological effects of statins in human ath-
eroma were evaluated by Crisby et al. (15) in carotid
plaques 3 months before carotid endarterectomy.
They found decreased lipid oxidation, inflamma-
aracterize Fibrous Cap Thickness
en stained in red color. (B) Thick cap ﬁbroatheroma mostly com-
response to injury. Courtesy of K. Raman Purushothaman, MD,Ch
ollag
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180tion, matrix metalloproteinase-2, and cell death in
plaques from patients taking the medication. In
addition, increased tissue inhibitor of metallopro-
teinase-1, and collagen content was also docu-
mented, confirming plaque-stabilizing effects in
humans. More recently, Puato et al. (16) studied
cellular changes using the same protocol. Signifi-
cant reductions on macrophage infiltration along
with increases in smooth muscle cells were docu-
mented with just 3 months of high-dose statin
therapy (16).
Mechanisms of Plaque Regression:
Resolution of Inﬂammation and Efferocytosis
Monocytes-derived macrophages are responsible
for disease progression, and their role in plaque
regression is evolving rapidly. Monocytes can
differentiate into those that promote inflamma-
tion, which are referred to as classically activated
(M1) macrophages, and those than promote res-
olution of inflammation and collagen synthesis,
also referred as alternatively activated (M2) mac-
rophages (17). Supported by T-helper 1 lympho-
cytes (hence the name M1 macrophages), these
proinflammatory phagocytes are associated with
insulin resistance, secretion of matrix metallopro-
teinases, thinning of fibrous cap, and plaque
rupture. In contrast, M2 macrophages are sup-
ported by T-helper 2 lymphocytes, and are asso-
ciated with insulin sensitivity, removal of apop-
totic bodies from the plaque (efferocytosis), and
collagen synthesis by transforming growth factor
beta–mediated activity (17).
In the atherosclerotic lesions of apolipoprotein
E (ApoE)/ mice, resolution of inflammation is
not observed in the setting of hypercholesterol-
emia. However, when plaques are exposed to low
levels of cholesterol, plaque regression occurs. In
this model of atherosclerosis, exposure to low
cholesterol can be obtained by: 1) transplantation
of plaque-bearing aortae from the ApoE/ mice
into wild-type mice (18); and 2) treatment with
ApoE encoding adenoviral vectors, which nor-
malize plasma cholesterol to wild-type levels and
increase high-density lipoprotein levels 4-fold
(19). Using the transplant model, inflammatory
cell egression, and efferocytosis of apoptotic bod-
ies has been carefully studied. Dendritic cells
migrate through adventitial lymph vessels to local
lymph nodes in a process that is dependent on the
chemotactic ligands of the G protein-coupled
chemokine receptor-7 (CCR7) (20). A series of oinsightful observations in this transplant model
promoted CCR7 as the pivotal molecule of plaque
regression (21). The molecular mechanisms in-
volved the liver X receptor (responsible for the
high-density lipoprotein–dependent reverse cho-
lesterol transport), the MERTK engulfment re-
ceptor, and others (22,23). Using this transplant
model, atorvastatin and rosuvastatin promoted
clusters of differentiation CD68 cell emigra-
tion, increasing transcriptional activity and chro-
matin organization at the CCR7 promoter (24).
Simultaneously, the ApoE-encoding adenoviral
vector model identified a different pattern of
macrophage removal in the ApoE–/– mice model
25). Within 4 weeks of therapy, esterified cho-
esterol was significantly reduced. This was fol-
owed by a 72% reduction in macrophage content
ndependent of CCR7. Most importantly, a
arked inhibition of macrophage recruitment
rom circulating monocytes was achieved by sig-
ificant reductions in endothelial adhesion mol-
cules (25). As a result, suppressed monocyte
ecruitment, rather than CCR7 efferocytosis, may
e the predominant mechanism in plaque regres-
ion. In the absence of macrophage egression,
ocal proliferation of M2 macrophages may be
esponsible for clearance of apoptotic cells and trans-
orming growth factor beta–mediated collagen syn-
hesis (26).
Conclusions
The understanding of major reductions in coro-
nary events associated with aggressive medical
therapy is evolving rapidly. High-dose statin
therapy is associated with beneficial histological
changes in plaque composition in humans. As a
result, plaque regression is now carefully docu-
mented in vivo by multimodality novel imaging
technology. The cellular and molecular mecha-
nisms responsible for plaque regression in hu-
mans are less understood, but clearly involve
inhibition of macrophage recruitment, resolution
of inflammation, and new collagen synthesis.
More studies are needed to clearly elucidate this
issue.
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